Component

Human diabetic-neuropathy modified Toronto score

Human diabetic-neuropathy modified Toronto score

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The 2024 trial did not find a significant between-group mTCNS change at 12 weeks.

    Acetyl-L-carnitine → Human diabetic-neuropathy modified Toronto score Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "ALCAR hydrochloride through 12 weeks", "comparator": "Placebo", "endpoint": "The 2024 trial did not find a significant between-group mTCNS change at 12 weeks.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Same randomized trial; 12-week change −5.0 versus −4.3, P=0.120.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    The 2024 trial did not find a significant between-group mTCNS change at 12 weeks.
    primary_references
    Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377
    source_locator
    Reviewed reference dpn24-early-null; The later significant composite endpoint must not be back-projected to the earlier assessment.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 515–521

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Same randomized trial; 12-week change −5.0 versus −4.3, P=0.120. · Recorded from source · Recorded from source

    ### dpn24-early-null The 2024 trial did not find a significant between-group mTCNS change at 12 weeks. The later significant composite endpoint must not be back-projected to the earlier assessment. Model and exposure: Same randomized trial; 12-week change −5.0 versus −4.3, P=0.120. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  2. ALCAR hydrochloride improved the 24-week mTCNS composite more than placebo in the 2024 trial.

    Acetyl-L-carnitine → Human diabetic-neuropathy modified Toronto score Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "ALCAR hydrochloride 1,500 mg/day for 24 weeks", "comparator": "Placebo", "endpoint": "ALCAR hydrochloride improved the 24-week mTCNS composite more than placebo in the 2024 trial.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Multicenter China trial: 516 randomized; eight type-1 participants excluded from ITT/FAS analyses; FAS 505 (254 ALC,251 placebo). 1,500 mg/day for 24 weeks.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    ALCAR hydrochloride improved the 24-week mTCNS composite more than placebo in the 2024 trial.
    primary_references
    Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377
    source_locator
    Reviewed reference dpn24-score; Mean change −6.9 versus −4.7 points, P<0.001. The draft count of 458 randomized was incorrect. Trial medication was acetyllevocarnitine hydrochloride, 500 mg three times daily.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 507–513

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Multicenter China trial: 516 randomized; eight type-1 participants excluded from ITT/FAS analyses; FAS 505 (254 ALC,251 placebo). 1,500 mg/day for 24 weeks. · Recorded from source · Recorded from source

    ### dpn24-score ALCAR hydrochloride improved the 24-week mTCNS composite more than placebo in the 2024 trial. Mean change −6.9 versus −4.7 points, P<0.001. The draft count of 458 randomized was incorrect. Trial medication was acetyllevocarnitine hydrochloride, 500 mg three times daily. Model and exposure: Multicenter China trial: 516 randomized; eight type-1 participants excluded from ITT/FAS analyses; FAS 505 (254 ALC,251 placebo). 1,500 mg/day for 24 weeks. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.